Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • UK
  • +44 (0)20 8068 8176 Request Information
  • +44 (0)20 8068 8176 Request Information
United KingdomUnited Kingdom
  • We guide you
    • Fertility
    • Prevent inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • EMBRACE
      • PGT-M
      • POC
      • NACE
      • SAT
    • Patients
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • EMBRACE
      • PGT-M
      • POC
      • NACE
      • SAT
  • Diagnostics
    • Newborn Screening
    • Panels by specialities
  • About us
    • Igenomix Research
    • About Igenomix
  • Webinars
Genetic Solutions > PGT-A

PGT-A Preimplantation Genetic Testing for Aneuploidies

Improves the chances of reproductive success by selecting chromosomally normal embryos

  • Technical Overview
  • Documentation
  • Scientific evidence
  • I’m not a health specialist

+120,000 embryos
analyzed/year

Supporting over
12,000 IVF cycles/year

98% accuracy

Superior reviews from
independent studies

Are you interested?

Request information
Or email us at info.uk@igenomix.com
Overview
  • PGT-A
  • Benefits
  • Indications

What is PGT-A test?

PGT-A (formerly PGS) is a genetic test performed on embryos to identify numerical chromosomal abnormalities (aneuploidy).

Our PGT-A uses Next-Generation Sequencing (NGS), which allows us to analyse all 24 chromosomes. Chromosomal abnormalities are detected prior to embryo transfer to enable informed decisions and increase pregnancy success.

What is the procedure?

To meet the rigorous standards of our ISO 15189 accreditation, we must first validate embryologists who will be performing blastocyst biopsies. We will support you throughout this process and work with you to introduce PGT-A from Igenomix.

Once we have completed validation, we will provide you with kits for tubing embryo biopsy samples. Our laboratory and customer support team will work with you to ensure a smooth test request and collection process. We will then perform PGT-A in our accredited UK laboratory and release the report within 10 working days of receiving your samples. On average, this happens in 4 working days.

What diagnostic method is used in our PGT-A test?

By applying our unique Smart PGT-A technology, Igenomix is able to constantly refine and improve our ability to analyse embryo samples. We have have developed a proprietary Bioinformatic Calling algorithm based on over 100,000 embryo samples, which minimises human errors and bias/subjectivity.

Why use PGT-A?

  • Increases pregnancy rates per transfer:
    Selecting normal embryos can increase the pregnancy chances after transfer
  • Reduction in miscarriage rate:
    In the general population, 25% of all clinical pregnancies end in miscarriage, the vast majority of which are due to aneuploidy
  • Increase in the likelihood of having a healthy baby:
    Some pregnancies with chromosomal anomalies can give rise to the birth of baby with a serious illness
  • Reduction in time and necessary resources:
    The time and resources necessary to achieve a pregnancy are reduced
  • Reduces risk of multiple pregnancy:
    A SET significantly reduces the likelihood of a twin pregnancy

Why Igenomix PGT-A?

Independent studies have compared PGT-A from Igenomix and other labs and the highlights include:

Igenomix Mitoscore

MitoScore is a mitochondrial biomarker developed by Igenomix, which gives us an indicator of the energy status of an embryo.

MitoScore allows us to select those embryos with the greatest probabilities for implantation that are more likely to result in a viable pregnancy through IVF/ PGT-A.*

*(Diez-Juan et al. 2015)

The clinical translation of this work is the integration of the mtDNA copy number (MitoScore) with the routine genetic analysis performed in the PGT-A process.

Who should use PGT-A?

  • PGT-A is particularly important for patients over 35, as aneuploidy rate increases with maternal age.
  • PGT-A also can greatly reduce the likelihood of a patient having a multiple-gestation pregnancy by choosing a Single Embryo Transfer (SET).

Test limitations

PGT-A does not test for:

Birth defects
Inherited single gene disorders, such as cystic fibrosis or Tay-Sachs disease
Multifactorial conditions, including autism
Adult-onset conditions such as diabetes or Alzheimer´s disease
Physical and mental traits, such as intelligence or athleticism
Microdeletions/microduplications

As with most tests, PGT-A has some limitations:

1. Accuracy is ~98%

  • False positive: There is a small chance an embryo could be excluded unnecessarily
  • False negative: There is a small chance that an embryo diagnosed as normal could still be chromosomally abnormal

2. PGT-A tests only the samples produced by embryo biopsy, not whole embryos

3. PGT-A does not detect structural abnormalities that do not involve gains or losses of genetic material. Additionally, the following cannot be detected:

  • Chromosome losses/gains bellow 10Mb,
  • Low level of mosaicism (<30%)
  • Uniparental disomy (UDP)
  • Defects affecting the complete set of chromosomes (haploidy, triploidy)

Follow-up prenatal testing is recommended to confirm the results of PGT-A.

There is a chance of unforeseeable problems with transportation, such as weather and air travel issues, or other circumstances beyond the control of Igenomix that may delay the reporting of results.

In a small percentage of cases, genetic testing cannot be performed due to improper biopsy techniques, loss of biopsied cells, or poor DNA quality.

Documentation
  • PGT-A Specialists’ documents

Brochure

Download

Mitoscore

Download
Scientific evidence
  • Igenomix
  • External

Title: In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study

Authors: Rubio C, Bellver J, Rodrigo L, Castillón G, Guillén A, Vidal C, Giles J, Ferrando M, Cabanillas S, Remohí J,Pellicer A, Simón C

Publication: Fertil Steril. 2017 May;107(5):1122-1129. doi: 10.1016/j.fertnstert.2017.03.011. Epub 2017 Apr 19.

PMID: 28433371

Title: Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study

Authors: Yang Z, Liu J, Collins G S, Salem S A, Liu X, Lyle S S, Peck A C, Sills E S, Salem R D

Publication: Mol Cytogenet. 2012 May 2;5(1):24. doi: 10.1186/1755-8166-5-24.

PMID: 22551456

Title: Optimal euploid embryo transfer strategy, fresh versus frozen, after preimplantation genetic screening with next generation sequencing: a randomized controlled trial

Authors: Coates A, Kung A, Mounts E, Hesla J, Bankowski B, Barbieri E, Ata B, Cohen J, Munné S

Publication: Fertil Steril. 2017 Mar;107(3):723-730.e3. doi: 10.1016/j.fertnstert.2016.12.022. Epub 2017 Jan 27.

PMID: 28139240

Title: Differences in pregnancy outcomes in donor egg frozen embryo transfer (FET) cycles following preimplantation genetic screening (PGS): a single center retrospective study

Authors: Coates A, Bankowski B J, Kung A, Griffin D K, Munne S

Publication: J Assist Reprod Genet. 2017 Jan;34(1):71-78. doi: 10.1007/s10815-016-0832-z. Epub 2016 Nov 16.

PMID: 27853913

Sanchez-Ribas et al., Transcriptomic behavior of genes associated with chromo some 21 aneuploidies in early embryo development. Fertility and Sterility, 2019; 111, 5:991-1001. 

Goldwaser, Tamar et al. Cell-free DNA for the detection of fetal aneuploidy. Fertility and Sterility, 2018; 109, 2, 195 – 200. 

Kuznyetsov V, Madjunkova S, Antes R, Abramov R, Motamedi G, Ibarrientos Z, et al.  Evaluation of a novel non-invasive preimplantation genetic screening approach. PLoS ONE; 2018; 13(5): e0197262. 

Munné S, Status of preimplantation genetic testing and embryo selection. RBMO. 2018; 37(4):393-396. 

Levy et al., Prenatal diagnosis by chromosomal microarray analysis. Fertility and Sterility, 2017; 109, 2, 201–212.  

Ottolini C. et al., Scientific Reports. Tripolar mitosis and partitioning of the genome arrests human preimplantation development in vitro, 2017;7:9744. 

Ottolini C. et al., Scientific Reports. Tripolar mitosis and partitioning of the genome arrests human preimplantation development in vitro, 2017;7:9744. 

Munné, Santiago et al. Mosaicism: “survival of the fittest” versus “no embryo left behind”. Fertility and Sterility, 2016; 105, 5, 1146 – 1149. 

Bolton et al., Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal developmental potential. Nature Communications, 2016; 29;7:11165. 

Cimadomo D. et al, The Impact of Biopsy on Human Embryo Developmental Potential during Preimplantation Genetic Diagnosis. Hindawi, 2016, 7193075. 

Scott RT, Galliano D., The challenge of embryonic mosaicism in preimplantation genetic screening. Fertility and Sterility, 2016; 105, 5. 

McCoy RC, Demko ZP, Ryan A, Banjevic M, Hill M, Sigurjonsson S, et al.  Evidence of Selection against Complex Mitotic-Origin Aneuploidy during Preimplantation Development. PLoS Genet, 2015; 11 (10): e1005601.  

Kung A. et al., Validation of next-generation sequencing for comprehensive chromosome screening of embryos. Reproductive BioMedicine, 2015; 1472-6483. 

Greco E, Minasi MG, Fiorentino F. Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts, N Engl J Med, 2015; Nov 19;373(21):2089-90.  

Yang Z et al., Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study., 2012, 5:24. 

If you're a little lost with this technical information...

Can we help you?

I’m not a health specialist

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services you may be interested in

ERA

Evaluates the endometrial receptivity

More information

EMMA

Evaluates the endometrium at the microbiological level

More information

ALICE

Detects the bacteria causing chronic endometritis

More information

Igenomix is in the media

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

Click to view our ISO: 15189 accreditation

OUR SERVICES

Genetic solutions
For patients
Sending samples and documentation

ABOUT US

About Igenomix
Contact
User manual

Work with us

FOLLOW IGENOMIX

  020 8068 8176
Email us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Language

[2022] © Igenomix Privacy policy Quality policy Legal note Cookies policy       User feedback     Complaints form

Request Information

         
 
   

  • We guide you
    • Fertility
    • Prevent inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • EMBRACE
      • PGT-M
      • POC
      • NACE
      • SAT
    • Patients
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • EMBRACE
      • PGT-M
      • POC
      • NACE
      • SAT
  • Diagnostics
    • Newborn Screening
    • Panels by specialities
  • About us
    • Igenomix Research
    • About Igenomix
  • Webinars
  • UK